Effect of using fidaxomicin on recurrent Clostridium difficile infection
Research output: Contribution to journal › Article
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
|Number of pages||3|
|Journal||The Journal of hospital infection|
|Early online date||4 Jan 2019|
|Publication status||Published - Jun 2019|
- clostridium difficile, recurrence, fidaxomicin